サンプル依頼リスト カート
  • English
  • Korean
表紙：オピオイド薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1297821

オピオイド薬の世界市場-2023年～2030年

Global Opioids Drug Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.33円
オピオイド薬の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のオピオイド薬市場は、2022年に399億9,830万米ドルに達し、2030年には516億3,470万米ドルに達する好成長が予測されています。世界のオピオイド薬市場は、予測期間中（2023-2030年）に3.3%のCAGRを示すと予測されています。

オピオイド薬は、中等度から重度の疼痛管理、特に手術や怪我後の急性疼痛、がん関連の疼痛、進行した病気の患者の緩和ケアのために一般的に処方されています。オピオイドはまた、オピオイド使用障害のある患者に対する薬物療法（MAT）の一環として使用されることもあります。

さらに、世界のオピオイド薬市場の成長に寄与する主な促進要因は、激しく苦しむ患者に対する緩和ケアの拡大と、オピオイドの乱用を制限するための乱用抑止製剤の使用です。また、手術後の疼痛、がん、線維筋痛症、腰痛、関節炎などの慢性疼痛関連疾患の発生が増加していることも、これらの疾患の有病率上昇に寄与しています。

市場力学

メンタルヘルス疾患の増加がオピオイド薬市場の成長を牽引すると予想されます

国連報告書2022によると、世界中で10億人近くが何らかの精神障害に苦しんでいます。さらに、COVID-19パンデミックの最初の年には、うつ病や不安症などの一般的な疾患の割合が25％以上上昇しました。

精神障害を併発している人は、自己治療としてオピオイドを求めやすいです。米国精神医学会は、オピオイドは多幸感を誘発し、否定的な結果にもかかわらず使用を続ける可能性を高めると述べています。

オピオイドの蔓延、自殺率の上昇、精神衛生上の問題は相互に関連しており、慢性疼痛を抱える人は、精神衛生上の障害をより高い割合で経験することが多いです。オピオイドの自己治療目的での使用を防ぎ、物質使用障害と精神疾患の両方に対して適切な治療を提供するためには、オピオイド使用障害を治療する際に、根本的な精神疾患に対処することが極めて重要です。

オピオイド薬のリスクと副作用が世界のオピオイド薬市場の成長を妨げています

オピオイド薬には、いくつかのリスクと潜在的な副作用があります。オピオイドの長期使用は、身体的依存や中毒につながる可能性があり、その特徴として、切望感や中止時の離脱症状があります。また、オピオイドは呼吸器系を抑制する可能性があり、高用量や他の呼吸抑制薬と併用した場合、呼吸が遅くなったり、呼吸停止を引き起こす可能性さえあります。

例えば、モルヒネは天然のオピオイドであり、最も古くから知られている鎮痛薬のひとつです。病院では激痛緩和のために頻繁に使用されています。モルヒネの長期使用は、依存症や中毒を引き起こす可能性があります。したがって、上記の要因のために、市場は予測期間中に低迷すると予想されます。

COVID-19影響分析

COVID-19の大流行は、オピオイド薬の使用と入手に大きな影響を与えています。パンデミックは世界中のヘルスケアシステムを混乱させ、薬物乱用治療や支援を含む必要不可欠なサービスへのアクセスに影響を与えました。多くの依存症治療センターや診療所は、対面診療の制限や一時的な閉鎖を余儀なくされ、オピオイド依存症と闘う人々にとって不可欠な資源へのアクセスが減少しました。

パンデミックは、かつてないレベルのストレス、不安、社会的孤立をもたらしました。これらの要因は、既存の薬物使用障害を悪化させ、オピオイドの誤用を開始または拡大させる一因となります。経済的苦難、失職、悲嘆、限られた社会的支援ネットワークはすべて、物質使用の増加とオピオイド中毒への脆弱性の原因となりうる。

パンデミックに対応するため、ヘルスケア提供者は遠隔医療をますます利用し、遠隔診察や処方サービスを提供するようになっています。遠隔医療はヘルスケアへのアクセスを維持するのに役立ったが、オピオイド薬の適切な使用を監視・規制する上で課題も生じた。場合によっては、十分な評価やフォローアップ、監視がないまま遠隔処方が増加し、不適切あるいは過剰なオピオイド処方につながる可能性もあっています。

ロシア・ウクライナ紛争分析

ウクライナとロシアの紛争は、世界のオピオイド薬市場に直接的な影響を及ぼしていないです。しかし、オピオイドを含む違法薬物取引は、特定の地域における紛争や不安定化など、様々な地政学的要因の影響を受ける可能性があることに留意することが重要です。

一般的に、薬物の生産や密売活動が行われている地域での紛争や混乱は、薬物の入手可能性や供給ルートに影響を与える可能性があります。紛争によって、麻薬の密売ルートが変化したり、違法物質の生産や流通が変化したりする可能性があります。こうした変化は、オピオイドの入手可能性や価格設定を含め、世界の薬物市場に波及効果をもたらす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • メンタルヘルス疾患の増加
    • 抑制要因
      • オピオイド薬のリスクと副作用
    • 機会
      • オピオイド分野の継続的研究
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 製品別

  • ブプレノルフィン
  • フェンタニル
  • ヒドロコドン
  • モルヒネ
  • オキシコドン
  • その他

第9章 用途別

  • 疼痛管理
  • 麻酔
  • 咳止め
  • 下痢治療
  • オピオイド中毒治療
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東およびアフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • Purdue Pharma L.P.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Janssen Pharmaceuticals, Inc.
  • West-Ward Pharmaceuticals Corporation
  • Pfizer Inc.
  • Cipher Pharmaceuticals Inc.
  • Lupin Ltd.
  • Allergan PLC
  • Sanofi-Aventis S.A.
  • Sun Pharmaceutical Industries Limited
  • Grunenthal GmbH

第14章 付録

目次
Product Code: PH3002

Market Overview

The global opioids drug market reached US$ 39,998.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 51,634.7 million by 2030. The global opioids drug market is expected to exhibit a CAGR of 3.3% during the forecast period (2023-2030).

Opioid drugs are commonly prescribed for the management of moderate to severe pain, particularly acute pain following surgeries or injuries, cancer-related pain, and palliative care for patients with advanced illnesses. Opioids may also be used as part of medication-assisted treatment (MAT) for individuals with opioid use disorders.

Furthermore, the key drivers contributing to the global opioid drug market's growth are escalating palliative care for patients suffering intensely and using abuse-deterrent preparations to restrict opioid abuse. Also, the growing occurrence of chronic pain-related conditions like post-surgical pain, cancer, fibromyalgia, lower back pain, and arthritis is contributing to the increasing prevalence of these diseases.

Market Dynamics

Increasing Mental Health Conditions are Expected to Drive Opioid Drugs Market Growth.

According to United Nations Report 2022, Nearly one billion people worldwide suffer from some form of mental disorder. Moreover, in the first year of the COVID-19 pandemic, rates of common conditions such as depression and anxiety went up by more than 25 percent.

Individuals who have co-occurring mental health disorders are more susceptible to seeking opioids as a form of self-medication. The American Psychiatric Association states that opioids can induce feelings of euphoria, increasing the likelihood of continued use despite negative consequences.

The opioid epidemic, rising suicide rates, and mental health issues are interconnected, and individuals with chronic pain often experience higher rates of mental health disorders. It is crucial to address underlying mental health conditions when treating opioid use disorder to prevent the use of opioids for self-medication and provide appropriate treatment for both the substance use disorder and the mental health condition.

The Risks and Side Effects of Opioid Drugs are Hampering the Growth of the Global Opioid Drugs Market.

Opioid drugs carry several risks and potential side effects, including prolonged use of opioids can lead to physical dependence and addiction, characterized by cravings and withdrawal symptoms upon discontinuation and opioids can depress the respiratory system, potentially causing slowed breathing or even respiratory arrest in high doses or when combined with other respiratory depressants.

For instance, morphine is a natural opioid and one of the oldest known pain medications. It is frequently used in hospital settings for severe pain relief. Prolonged use of morphine can lead to dependence and addiction. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the use and availability of opioid drugs. The pandemic has disrupted healthcare systems worldwide, affecting access to essential services, including substance abuse treatment and support. Many addiction treatment centers and clinics had to limit in-person visits or temporarily close, reducing access to vital resources for individuals struggling with opioid addiction.

The pandemic has brought about unprecedented levels of stress, anxiety, and social isolation. These factors can exacerbate existing substance use disorders and contribute to the initiation or escalation of opioid misuse. Financial hardships, loss of employment, grief, and limited social support networks can all contribute to increased substance use and vulnerability to opioid addiction.

In response to the pandemic, healthcare providers increasingly turned to telemedicine to provide remote consultations and prescription services. While telemedicine helped maintain access to healthcare, it also presented challenges in monitoring and regulating the appropriate use of opioid medications. In some cases, there may have been an increase in remote prescribing without adequate assessments, follow-up, or oversight, potentially leading to inappropriate or excessive opioid prescriptions.

Russia-Ukraine Conflict Analysis

The Ukraine and Russia conflict has not had a direct impact on the global opioid drug market. However, it is important to note that the illicit drug trade, including opioids, can be influenced by various geopolitical factors, including conflicts and instability in certain regions.

In general, conflicts and disruptions in regions with drug production or trafficking activities can affect the availability and routes of drug supply. It is possible that conflicts can lead to shifts in drug trafficking routes or changes in the production and distribution of illicit substances. These changes can have ripple effects on the global drug market, including the availability and pricing of opioids.

Segment Analysis

The global opioid drugs market is segmented based on product, application, distribution channel, and region.

The Pain Management Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.

The pain management segment accounted for the highest market stake accounting for approximately 37.8% of the opioid drugs market. Opioid drugs offer several advantages in pain management, particularly for acute and severe pain. They work by binding to opioid receptors in the brain and spinal cord, reducing the transmission of pain signals and producing analgesic effects. This makes them valuable for managing pain after surgery, traumatic injuries, or during end-of-life care.

They are available in various formulations, allowing for flexibility in dosing and administration. They come in immediate-release forms, extended-release formulations, transdermal patches, oral solutions, and injectable formulations. This versatility allows healthcare providers to tailor the treatment to individual patient needs and optimize pain management.

For instance, morphine and fentanyl, have a rapid onset of action. This quick pain relief can be crucial in acute situations where immediate pain control is required, such as during surgical procedures or severe injuries.

Furthermore, opioids can effectively manage breakthrough pain, which refers to sudden and intense episodes of pain that occur despite ongoing pain management. Quick-acting opioids, such as immediate-release morphine or oxycodone, can be used as rescue medications to provide rapid relief during these episodes. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

The Rising Incidence of Orthopedic Diseases, the Increasing Prevalence of Chronic Diseases, and the Presence of Key Market Players Dominate the North American Region

North America is estimated to hold around 42.4% of the total market share throughout the forecast period. For instance, according to U.S. Pain Foundation Report 2022, approximately 50 million Americans experience chronic pain, lasting for three months or more on most days. Among them, 20 million individuals have high-impact chronic pain, which hinders their ability to perform basic daily activities, including personal hygiene and household chores.

The financial implications of pain are substantial, with estimates suggesting that it costs the nation a minimum of $560-635 billion annually in terms of direct medical expenses and productivity losses. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., West-Ward Pharmaceuticals Corporation, Pfizer Inc., Cipher Pharmaceuticals Inc., Lupin Ltd., Allergan PLC, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited, Grunenthal GmbH, and China Aoxing Pharmaceutical Company, Inc. among others.

Why Purchase the Report?

  • To visualize the global opioids drug market segmentation based on the product, application, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of opioids drug market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global opioids drug market report would provide approximately 61 tables, 62 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing mental health conditions
    • 4.1.2. Restraints
      • 4.1.2.1. The risks and side effects of opioid drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Ongoing research in the field of opioids
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Product

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Buprenorphine*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Fentanyl
  • 8.4. Hydrocodone
  • 8.5. Morphine
  • 8.6. Oxycodone
  • 8.7. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Pain management*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Anesthesia
  • 9.4. Cough suppression
  • 9.5. Diarrhea treatment
  • 9.6. Opioid addiction treatment
  • 9.7. Others

10. By Distribution Channel

    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. Purdue Pharma L.P.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Janssen Pharmaceuticals, Inc.
  • 13.3. West-Ward Pharmaceuticals Corporation
  • 13.4. Pfizer Inc.
  • 13.5. Cipher Pharmaceuticals Inc.
  • 13.6. Lupin Ltd.
  • 13.7. Allergan PLC
  • 13.8. Sanofi-Aventis S.A.
  • 13.9. Sun Pharmaceutical Industries Limited
  • 13.10. Grunenthal GmbH

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us